Report Overview

The EU Human Rotavirus Vaccine Market size stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period

Rotavirus refers to a virus that mostly infects infants & childrens causing diarrhea. This is a contagious virus that shows its symptoms within two or three days of exposure to the virus. Initial symptoms of this infection are fever, vomiting, followed by diarrhea, and abdominal pain. The vaccines are used to help increase the immune system of the body and lowers the severity of an infection. The vaccination starts around six weeks of age and this should be done along with the promoting several activities such as handwashing, clean water, good sanitation, and breastfeeding

Market Drivers

Major factors for the Europe Human Rotavirus Vaccine market are increase in the awareness regarding vaccines among patients can accelerate the growth of this market. Rise in the population of immunity-compromised individuals can act as a catalyst for the market growth. Increase in the development and manufacturing of vaccine would enhance the market growth. Rise in the geriatric population has driven the growth